You are here

Content

Karen Bieback, PhD

Our research interests focus on regenerative medicine, especially the development of novel cell based therapies (advanced therapy medicinal products – ATMP). Within the last years this field has been marked by significant achievements, further boosted by awarding the two stem cell researchers S. Yamanaka and J. Gurdon with the 2012 Nobel Prize in Medicine.

We are in particular fascinated by two cell populations due to their promising wide therapeutic spectra in vascular and regenerative medicine: mesenchymal stromal cells (MSC) and endothelial progenitor cells (EPC).

Our special interests are:

  • to understand the source and the regenerative properties of these cells
  • to optimize their proliferative and functional capacities focusing on potential therapeutic targets in vascular and regenerative medicine
  • to identify and optimize the mechanisms of action, especially immunomodulatory and pro-regenerative factors
  • to better understand homing and engraftment to be able to modulate these processes
  • to manufacture cells for clinical studies in vascular medicine according to good manufacturing practice (GMP) guidelines

Beyond this we are running the Core Facility for Flow Cytometry and Cell Sorting, initiated in 2007 by a HBFG grant. The facility belongs to the Centre for Biomedicine and Medical Technology (CBTM) and is open to researchers to perform cell sorting and flow cytometry experiments.

Multiphoton-microscopy of endothelial colony forming cells stained against CD34 (AF647), CD45 (AF547) und CD31 (AF488). The co-expression of the hematopoietic marker CD45 suggests a common ancestor of endothelial and hematopoietic cells (from Bieback et al. Cytotherapy 2013).

Project-related publications

  1. Wuchter P, Bieback K, Schrezenmeier H, Bornhäuser M, Müller LP, Bönig H, Wagner W, Meisel R, Pavel P, Tonn T, Lang P, Müller I, Renner M, Malcherek G, Saffrich R, Buss EC, Horn P, Rojewski M, Schmitt A, Ho AD, Sanzenbacher R, Schmitt M. Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy, 17:128-39, 2015.
  2. Kinzebach S, Dietz L, Klüter H, Thierse HJ, Bieback K. Functional and differential proteomic analyses to identify platelet derived factors affecting ex vivo expansion of mesenchymal stromal cells. BMC Cell Biol,14:48, 2013
  3. Bieback K, Vinci M, Elvers-Hornung S, Bartol A, Gloe T, Czabanka M, Klüter H, Augustin H, Vajkoczy P. Recruitment of human cord blood-derived endothelial colony-forming cells to sites of tumor angiogenesis. Cytotherapy, 15:726-39, 2013.
  4. Karagianni M, Brinkmann I, Kinzebach S, Grassl M, Weiss C, Bugert P, Bieback K. A comparative analysis of the adipogenic potential in human mesenchymal stromal cells from cord blood and other sources. Cytotherapy, 15:76-88, 2013.
  5. Dreher L, Elvers-Hornung, S Brinkmann I, Huck V, Henschler R, Gloe T, Klüter H, Bieback K. Cultivation in human serum reduces adipose tissue-derived mesenchymal stromal cell adhesion to laminin and endothelium and reduces capillary entrapment. Stem Cells Dev, 22:791-803, 2013.
  6. Bieback K, Hecker A, Schlechter T, Hofmann I, Brousos N, Redmer T, Besser D, Klüter H, Müller AM, Becker M. Replicative aging and differentiation potential of human adipose tissue-derived mesenchymal stromal cells expanded in pooled human or fetal bovine serum. Cytotherapy, 14:570-83, 2012.
  7. Bieback K, Ha VA, Hecker A, Grassl M, Kinzebach S, Solz H, Sticht C, Klüter H, Bugert P. Altered gene expression in human adipose stem cells cultured with fetal bovine serum compared to human supplements. Tissue Eng Part A., 16:3467-84, 2010.
  8. Bieback K, Hecker A, Kocaömer A, Lannert H, Schallmoser K, Strunk D, Klüter H. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells, 27:2331-41, 2009.
  9. Kocaömer A, Kern S, Klüter H, Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells, 25:1270-8, 2007.
  10. Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells, 24:1294-301, 2006.

Context Column